MEDIVIR AB – INTERIM REPORT JANUARY – MARCH 2020

Positive results for MIV-818 and continued tempo in business developmentJanuary – March Significant events during the quarter · Data from the phase Ia study with MIV-818 in liver cancer patients presented at Medivir’s R&D-day on March 2. The analysis supported the liver-targeted effect of MIV-818. Biomarker analysis showed a selective effect: while tumor tissue had clear DNA damage, healthy liver tissue showed only minimal or no DNA damage. Five of the nine patients were assessed to have stable liver disease after treatment. · The first liver cancer patient included in the MIV-